Title:
PHARMACEUTICAL COMPOSITION FOR FIBROSIS TREATMENT
Document Type and Number:
WIPO Patent Application WO/2023/248498
Kind Code:
A1
Abstract:
Provided is a fibrosis treatment agent including, as an active ingredient, a nucleic acid that inhibits the expression of the NDR2 gene.
Inventors:
ITO MINORU (JP)
MATOBA TOSHIHIRO (JP)
HORIMOTO SATOSHI (JP)
NAKAMURA KAZUTAKA (JP)
TSUTSUI YUSUKE (JP)
OKADA KAZUYUKI (JP)
MATOBA TOSHIHIRO (JP)
HORIMOTO SATOSHI (JP)
NAKAMURA KAZUTAKA (JP)
TSUTSUI YUSUKE (JP)
OKADA KAZUYUKI (JP)
Application Number:
PCT/JP2022/044980
Publication Date:
December 28, 2023
Filing Date:
December 06, 2022
Export Citation:
Assignee:
KYORIN SEIYAKU KK (JP)
International Classes:
A61K31/7105; A61K31/7088; A61K48/00; A61P1/16; A61P11/00; A61P13/12; C12N15/113
Foreign References:
| US20070031822A1 | 2007-02-08 | |||
| US20130089538A1 | 2013-04-11 | |||
| US20150141485A1 | 2015-05-21 |
Other References:
REN LONG, CHEN XI, NIE BINYANG, QU HUAN, JU JIAMING, BAI YUNLONG: "Ranolazine Inhibits Pyroptosis via Regulation of miR-135b in the Treatment of Diabetic Cardiac Fibrosis", FRONTIERS IN MOLECULAR BIOSCIENCES, vol. 9, XP093121244, ISSN: 2296-889X, DOI: 10.3389/fmolb.2022.806966
WANG HONGTAO; JIANG WEI; HU YANCHAO; WAN ZHAOFEI; BAI HONGYUAN; YANG QIANG; ZHENG QIANGSUN: "Quercetin improves atrial fibrillation through inhibiting TGF-β/Smads pathway via promoting MiR-135b expression", PHYTOMEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 93, 26 September 2021 (2021-09-26), AMSTERDAM, NL , XP086864455, ISSN: 0944-7113, DOI: 10.1016/j.phymed.2021.153774
WANG HONGTAO; JIANG WEI; HU YANCHAO; WAN ZHAOFEI; BAI HONGYUAN; YANG QIANG; ZHENG QIANGSUN: "Quercetin improves atrial fibrillation through inhibiting TGF-β/Smads pathway via promoting MiR-135b expression", PHYTOMEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 93, 26 September 2021 (2021-09-26), AMSTERDAM, NL , XP086864455, ISSN: 0944-7113, DOI: 10.1016/j.phymed.2021.153774
Attorney, Agent or Firm:
HASEGAWA Yoshiki et al. (JP)
Download PDF: